Introduction
Prostate cancer is the most commonly diagnosed cancer in men, 1 its incidence has risen dramatically in recent times, and it is felt that this trend will continue as the population ages. It is known that up to half of those men with prostate cancer will develop incurable disease 2 and of this group of patients, 10 -20% will have distant metastasis at presentation. 3 Many patients with prostate cancer are commenced on hormonal therapy; this can achieve tumour suppression for a time period of months to years. When tumour suppression can no longer be achieved, the prognosis is bleak for these hormone refractory patients. As current regiments have only a transient effect, many of these patients seek alternative treatments, one such being PC-SPES.
Epidemiological studies in the USA have suggested a strong dietary factor in the development of prostate cancer. 4 Studies such as these point to the fact that dietary agents may help in preventing the occurrence or progression of this disease. This therefore supports the search for dietary or herbal supplements that could be used in the treatment of prostate cancer. A variety of herbal therapies for cancer are sold in natural health stores and many of these treatments are used as dietary supplements by cancer patients. In fact, the number of patients looking to alternative treatment, was the subject of a study conducted by Eisenberg in 1993, 5 in it, it was revealed that there were 425 million visits to providers of alternative treatment during 1992 in America, it is felt that this number has increased since then. These therapies are sold as nutritional supplements for numerous illnesses, including the common cold, benign prostatic hypertrophy (saw palmetto) 6 and depression (Saint John's wort). 7 For the treatment of hormone refractory prostate cancer, a variety of products are available. In this review article we will be considering a herbal product, known as PC-SPES which is sold in many natural food and health stores, and is currently in vogue.
What is PC-SPES?
PC-SPES has been commercially available since November 1996 and is a combination of eight different herbs contained in a 320 mg gelatin capsule. The extracts are: Chrysanthemum morifolium, Ganoderma lucidum (a root fungus), Glycyrrhiza glabra (Spanish liquorice), Isatis indigotica, Panax pseudoginseng, Rabdosia rubescens, Scutellaria baicalensis and Serona repens (saw palmetto). 8 Each of these herbs individually seems to have some anti-tumour effect. Isatis indigotica contains beta-sitosterol, this is a phytosterol that is a constituent of legumes (bean family). The consumption of this has been shown to reduce cancer growth in animal studies by Kellis et al in 1984 . 9 Glycyrrhiza glabra is a Chinese herb which contains saponin and quercetin, there is some evidence that saponin can stimulate the immune system and quercetin has shown anti cancer effects. 10 This herb lowers serum testosterone levels and increases oestrogen levels by inducing the enzymes 17 beta-hydroxysteroid dehydrogenase and aromatase. 10 Panax pseudoginseng contains saponins that are believed to enhance immunity by stimulating the activity of natural killer cells. 11 Ganoderma lucidum contains high molecular weight polysaccharides and inhibits the growth of sarcoma. 12 Scutellaria baicalensis contains the saponin baicalein, which inhibits cancer cell multiplication and induces apoptosis in vitro. 12 Chrysanthemum morifolium is a less well-known substance with unspecified biological effects. Saw palmetto is a natural product, which decreases the bioavalability of testosterone in vivo. This herb has also been shown to have beneficial effects on patients with prostatic hyperplasia. 13 Rabdosia rubesrens has multiple anti-tumour and analgesic effects, it has been shown to inhibit in vitro cervical cancer cells and lymphoma. 14 
PC-SPES as a treatment
There have been 116 clinical and laboratory based studies published to date on PC-SPES, as revealed by a MED-LINE search. There have not been any randomised controlled trials. Many of these studies contain very small numbers of patients, thus limiting the conclusions that can be drawn. In addition to this, it is not known what the most therapeutic dose of PC-SPES actually is, as direct comparisons between varying different doses regimes have not been evaluated as yet.
To date, the largest study was conducted by Small et al 15 They studied 33 men with androgen dependent prostate cancer and 37 men with androgen independent prostate cancer. Each of these patients received up to nine capsules of PC-SPES per day (each capsule being 320 mg), this is different from other studies where patients received three capsules of PC-SPES daily. No study has proven which dose is the most beneficial. The authors reported that all 33 of the androgen independent group experienced a fall in their prostate specific antigen (PSA) of > 80% and that 19 of the 37 with androgen independent prostate cancer had a > 50% decrease in their PSA. They concluded reporting that PC-SPES although requiring further study seemed to have activity in the treatment of both androgen dependent and independent prostate cancer and had an acceptable toxicity. Their claim of 'acceptable toxicity' should be questioned, in that, three of the original 70 developed a pulmonary embolus, two developed left ventricular dysfunction and four developed hypertriglyceridemia.
All other studies so far conducted only contain small numbers of patients, meaning that only limited conclusions can be drawn from them. An example of such a study being one conducted by De la Teille et al 16 who prospectively evaluated the response of 33 patients treated with PC-SPES. They reported that PSA levels were lower in 87% of the patients treated with PC-SPES by a mean of 52% after 2 months of treatment. Obviously, given the small patient numbers, lack of randomisation, and short follow-up time (range 1 -24 months), these promising results are open to debate and very little in the way of meaningful conclusions can be drawn from this study. Another example of this is a study again conducted by De la Teille et al 17 who looked at 69 men treated with PC-SPES. Again, their results were promising, in that after 2 months of PC-SPES, 82% of the patients had a decreased PSA and at subsequent PSA follow-up more than two thirds had a lower PSA with respect to their pre PC-SPES levels. Unfortunately, this trial along with others contained no placebo arm and involved only small numbers of patients and is therefore limited in the conclusive evidence that it can provide to support the use of PC-SPES in the treatment of hormone refractory prostate cancer.
Side effects
The known side effects of nipple tenderness, gynaecomastia, erectile dysfunction, hot flushes and thromboembolic complications have been reported with the use of PC-SPES. Table 1 summarises the reported side effects of some of the published PC-SPES studies (the side effects of the Small et al study 15 are noted above).
There are differences in the frequency of side effects between the different studies, and Pfeifer et al 18 postulated the reasons for this. They felt that the difference in the numbers of patients experiencing breast tenderness, between their study and that of DiPaola 19 could be because Pfeifer et al placed all 16 of their patients on, or continued them on androgen ablation therapy. Of these 14 received an LHRH agonist with or without an anti androgen, and two had orchidectomies. They felt that being on hormonal therapy could account for the differences noted, and they also felt that dietary differences could contribute. This is supported by the fact that Chinese patients with prostate cancer rarely report breast tenderness when taking PC-SPES possibly due to the fact that they have a diet typically rich in fibre and low in fat. 
Discussion
The prognosis is bleak for those patients with hormone refractory prostate cancer, current treatment regimens have only a transient effect, and therefore these patients seek alternative treatments. Included in this group of alternative treatments is PC-SPES. As reported by Pfeifer et al 18 patients taking PC-SPES had decreased pain scores and their intake of analgesics was less than before starting the herbal preparation. It appears that the pain relief is as a direct consequence of the PC-SPES as, the preparation has been demonstrated to be free of any analgesic drug admixture. This effect could be due to Glycyrrhiza glabra, Ganoderma lucidum, Rabdosia rubescens and Panax pseudoginseng components of PC-SPES, which are known to have anti-inflammatory and analgesic properties.
Most studies in which patients are taking PC-SPES have reported around a 40 -50% reduction in the PSA, this would suggest that as a treatment it is effective. Heish et al 20 recorded that in, in vitro studies PC-SPES reduced intracellular and secreted forms of PSA. It was demonstrated by DiPaola et al 19 that PC-SPES decreased PSA levels in a study of eight patients with hormone sensitive disease. In this study patients discontinued any form of anti androgen treatment, which may have effected the result, given the known effect of anti androgen withdrawal on PSA levels. DiPaola et al concluded that the observed side effects in their patients were caused by the potent oestrogenic activity of the phytoestrogens contained within the herbal preparation. Pfeifer et al 18 questioned this, they stated that considering the oestrogen receptor assay used in DiPaola's experiments, the final concentration of PC-SPES in the assay was 0.5 mg/ml. In comparison, the oestradiol concentration with the same oestrogenic activity is 2.72 6 10 7 mg/ml, that is a 1.8 million-fold greater oestrogenic potency for oestradiol. This they felt suggested that there was only a weak oestrogenic effect of the PC-SPES in the assay used. It is now accepted that the mechanism of action of PC-SPES is not solely due to its oestrogenic activity.
The exact mechanism to account for the action of PC-SPES is unknown, although several other proposed mechanisms are reported. These include: (i) the downregulation of the bcl-2 and bcl-6 genes, promoting apoptosis, 8 and (ii) enhancing the immune function by activating T-and B-cells, 21 the evidence for these mechanisms is not conclusive. Clearly further research is required.
Conclusions
Many patients are now turning to PC-SPES amidst claims that it reduces PSA levels, improves pain and appears to enhance quality of life. Despite this increase in its usage by patients there remain many unanswered questions regarding this herbal preparation. In order to answer these questions, a large scale randomised controlled trial needs to be conducted. Only then will we be able to judge whether PC-SPES has a role to play in the treatment of hormone refractory prostate cancer. Until this time, the authors feel that, we as 'practitioners of conventional medicine' should carefully counsel our patients as to the risks of taking PC-SPES, and in light of the significant risk of DVT, the authors recommend the prophylactic use of aspirin in those taking PC-SPES.
